ASX Share rice
Tue 21 Sep 2021 - 08:19:am (Sydney)

ZLD Share Price

ZELIRA THERAPEUTICS LIMITEDZLDPharmaceuticals, Biotechnology & Life Sciences

ZLD Company Information


Zelira Therapeutics Limited





GIC Industry:


GIC Sub Industry:



101 St Georges Terrace Perth WA Australia 6000


61 8 6558 0886

Founder & Chairman:

Mr. Osagie O. Imasogie Esq.

MD, Global CEO & Director:

Dr. Oludare Odumosu

Company Sec.:

Mr. Timothy Ryan Slate

Clinical Trial Consultant:

Dr. Patty Washer

Company Overview:

Zelira Therapeutics Limited, a bio-pharmaceutical company, engages in the development of cannabinoid-based medicines for the treatment of various medical conditions in Australia. The company is also involved in a human clinical trial program focused on insomnia, autism, and opioid reduction; and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer, as well as the potential for cannabinoid formulations to treat diabetes-associated cognitive decline. It offers formulations under the HOPE brand in Pennsylvania and Louisiana, as well as develops Zenivol, a cannabinoid-based medicine for treatment of chronic insomnia. Zelira Therapeutics has strategic partnerships with Curtin University; the Telethon Kids Institute; the University of Western Australia; St. Vincent's Hospital; the Children's Hospital of Philadelphia (CHOP) on opioid reduction study; HAPA Pharm BV; and Ethicann. The company was formerly known as Zelda Therapeutics Limited and changed its name to Zelira Therapeutics Limited in December 2019. Zelira Therapeutics Limited was founded in 2003 and is headquartered in Perth, Australia.

ZLD Share Price Information

Shares Issued:


Market Capitalisation:


Revenue (TTM):


Revenue Per Share (TTM):


Earnings per Share:


Operating Margin (TTM):


Return On Assets (TTM):


Return On Equity (TTM):


Quarterly Revenue Growth (YOY):


Gross Profit(TTM):


Diluted Earnings Per Share (TTM):


ZLD CashFlow Statement

CashFlow Date:




Change To Liabilities:


Total Cashflow From Investing Activities:


Net Income:


Total Cash From Operating Activities:




Other Cashflow From Investing Activities:


Change To Inventory:


Change To Account Receivables:


Sale Purchase Of Stock:


Capital Expenditures:


ZLD Income Statement

Income Date:


Income Before Tax:


Net Income:


Gross Profit:


Operating Income:


Other Operating Expenses:


Interest Expense:


Total Revenue:


Cost Of Revenue:


ZLD Balance Sheet

Balance Sheet Date:


Intangible Assets:


Total Liabilities:


Total Stockholder Equity:


Total Assets:


Common Stock:


Other Current Assets:


Retained Earnings:


Good Will:




Total Current Liabilities:


Property - Plant & Equipment:


Net Tangible Assets:


Long-Term Investments:


Total Current Assets:


Net Receivables:


Short-Term Investments:




Accounts Payable:


Short-Term Investments:


Non Current Liabilities Total:


ZLD Share Price History

ZLD News

29 Jun, 2021
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
31 Dec, 2020
Richard Hopkins has been the CEO of Zelira Therapeutics Limited ( ASX:ZLD ) since 2018, and this article will examine...
15 Dec, 2020
Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF), a global leader in the development of clinically validated cannabis medicines, is pleased to announce it has entered into a binding licensing agreement with Alternative Solutions, a licensed grower, manufacturer and distributor of medical cannabis products in the District of Columbia (Washington DC). Under the agreement, Alternative Solutions will produce and distribute the HOPE™ line of products, Zelira's top-selling treatment developed for autism patients, throughout the legal DC medical cannabis market beginning in Q2 2021.